tiprankstipranks
Advertisement
Advertisement
Alx Oncology Signals Promise, But Validation Looms
PremiumCompany AnnouncementsAlx Oncology Signals Promise, But Validation Looms
2M ago
Analyst Reiterates Buy on Evorpacept’s Biomarker-Driven Potential, Maintains $4 Price Target
Premium
Ratings
Analyst Reiterates Buy on Evorpacept’s Biomarker-Driven Potential, Maintains $4 Price Target
2M ago
ALX Oncology evorpacept combination data presented at ESMO congress
Premium
The Fly
ALX Oncology evorpacept combination data presented at ESMO congress
2M ago
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation
PremiumCompany AnnouncementsAlx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation
4M ago
ALX Oncology price target raised to $4 from $2 at H.C. Wainwright
Premium
The Fly
ALX Oncology price target raised to $4 from $2 at H.C. Wainwright
4M ago
Alx Oncology Earnings Call Highlights Biomarker Momentum
Premium
Company Announcements
Alx Oncology Earnings Call Highlights Biomarker Momentum
4M ago
ALX Oncology announces major underwritten public equity offering
PremiumCompany AnnouncementsALX Oncology announces major underwritten public equity offering
5M ago
ALX Oncology Highlights Biomarker Data and Cash Position
Premium
Company Announcements
ALX Oncology Highlights Biomarker Data and Cash Position
5M ago
ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
Premium
The Fly
ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100